Guobang Pharma Ltd. (SHA:605507)
China · Delayed Price · Currency is CNY 15.71
-0.10 (-0.63%)
Nov 6, 2026, 3:00 PM CST
Guobang Pharma Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 6,130 | 6,011 | 5,891 | 5,349 | 5,721 | 4,505 |
Revenue Growth | 3.16% | 2.05% | 10.12% | -6.49% | 26.98% | 7.11% |
Gross Profit Gross Profit Growth | 1,389 | 1,528 | 1,435 | 1,209 | 1,531 | 1,294 |
Operating Income Operating Income Growth | 754.41 | 914.38 | 835.91 | 629.3 | 949.97 | 815.55 |
Net Income Net Income Growth | 621.94 | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 |
Earnings Per Share EPS Growth | 0.81 | 1.06 | 1.00 | 0.79 | 1.18 | 0.99 |
EPS Growth | -27.82% | 5.71% | 27.27% | -33.34% | 19.57% | -19.30% |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 3,299 |
Overseas Overseas Growth | 2,688 |
Total Total Growth | 5,988 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,503 | 2,703 | 2,527 | 2,560 | 2,799 | 2,151 |
Total Debt Total Debt Growth | 952.93 | 997.5 | 780.12 | 969.37 | 664.28 | 168.88 |
Net Cash (Debt) Net Cash Growth | 1,550 | 1,705 | 1,747 | 1,591 | 2,134 | 1,982 |
Net Cash Growth | 23.95% | -2.37% | 9.81% | -25.46% | 7.66% | 528.79% |
Net Cash Per Share Net Cash Per Share Growth | 2.01 | 2.20 | 2.23 | 2.04 | 2.73 | 2.77 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 912.3 | 559.28 | 706.41 | 516.76 | 1,017 | -176.18 |
Capital Expenditures CapEx Growth | -360.3 | -277.71 | -419.12 | -748.44 | -803.12 | -448.04 |
Free Cash Flow Free Cash Flow Growth | 552 | 281.57 | 287.29 | -231.68 | 213.92 | -624.23 |
Free Cash Flow Growth | -7.55% | -1.99% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 22.66% | 25.43% | 24.37% | 22.60% | 26.76% | 28.72% |
Operating Margin | 12.31% | 15.21% | 14.19% | 11.76% | 16.61% | 18.10% |
Pretax Margin | 11.59% | 15.82% | 15.07% | 13.04% | 18.10% | 17.91% |
Profit Margin | 10.14% | 13.65% | 13.27% | 11.45% | 16.10% | 15.67% |
FCF Margin | 9.00% | 4.68% | 4.88% | -4.33% | 3.74% | -13.86% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.429 | 0.429 | 0.433 | 0.215 | 0.429 | 0.500 |
Dividend Per Share Growth | 38.65% | -0.95% | 100.88% | -49.74% | -14.28% | - |
Dividend Yield | 2.73% | 2.44% | 2.94% | 1.72% | 2.27% | 2.43% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.49 | 16.71 | 14.73 | 16.02 | 16.06 | 22.82 |
Forward PE | 16.89 | 13.21 | 10.92 | 11.33 | 12.98 | - |
P/FCF Ratio | 21.94 | 48.71 | 40.07 | - | 69.15 | - |
PS Ratio | 1.98 | 2.28 | 1.95 | 1.83 | 2.59 | 3.58 |